3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
11
Unknown
3
Recruiting
3
Active not recruiting
3
Terminated
2
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
20
Rectal Neoplasms
11
Colonic Neoplasms
9
Neoplasm Metastasis
7
Carcinoma, Hepatocellular
6
Pancreatic Neoplasms
5
Stomach Neoplasms
4
Recurrence
2
Esophageal Neoplasms
2
Adenocarcinoma Of Esophagus
2
Peritoneal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Motor Activity
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Liver Neoplasms
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophagogastric Cancer
1
Esophageal Squamous Cell Carcinoma
1
Clinical Stage I Gastric Cancer AJCC v8
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Borderline Resectable Pancreatic Adenocarcinoma
1
Biliary Tract Neoplasms
1
Adenocarcinoma
1
Interventions
nimotuzumab
4
Paclitaxel
3
Surgical Procedures, Operative
2
Cisplatin
2
sintilimab
1
pembrolizumab
1
monalizumab
1
epacadostat
1
Taxes
1
TP protocol
1
Saline Solution
1
Radiation
1
Oxaliplatin
1
Nimodipine
1
Metabolic Networks and Pathways
1
Fluorouracil
1
Biopsy
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Esophageal Squamous Cell Carcinoma
×
Oxaliplatin
×
Clear all
NCT03307941
2017-12-19
ARTEMIS-Eso
Jules Bordet Institute
Phase 1/2
Withdrawn